ANGLE plc (LON:AGL)‘s stock had its “corporate” rating reiterated by investment analysts at FinnCap in a report issued on Monday, Marketbeat Ratings reports. They currently have a GBX 100 ($1.33) price target on the stock, down from their prior price target of GBX 108 ($1.43). FinnCap’s target price would suggest a potential upside of 161.44% from the company’s previous close.

Separately, Beaufort Securities reiterated a “speculative buy” rating on shares of ANGLE plc in a report on Wednesday, July 5th.

Shares of ANGLE plc (AGL) traded down 0.65% during mid-day trading on Monday, reaching GBX 38.25. The company had a trading volume of 769,276 shares. ANGLE plc has a one year low of GBX 32.27 and a one year high of GBX 80.00. The stock has a 50 day moving average of GBX 36.93 and a 200-day moving average of GBX 48.70. The firm’s market capitalization is GBX 28.06 million.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/09/angle-plcs-agl-corporate-rating-reiterated-at-finncap.html.

ANGLE plc Company Profile

ANGLE plc is a holding company. The Company’s principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health.

Receive News & Stock Ratings for ANGLE plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANGLE plc and related stocks with our FREE daily email newsletter.